DSGN vs. COLL, PHVS, CALT, TLRY, ELVN, GPCR, NTLA, LENZ, RCUS, and ZYME
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Collegium Pharmaceutical (COLL), Pharvaris (PHVS), Calliditas Therapeutics AB (publ) (CALT), Tilray Brands (TLRY), Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Intellia Therapeutics (NTLA), LENZ Therapeutics (LENZ), Arcus Biosciences (RCUS), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.
Design Therapeutics vs. Its Competitors
Collegium Pharmaceutical (NASDAQ:COLL) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.
Collegium Pharmaceutical presently has a consensus target price of $42.33, indicating a potential upside of 10.39%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than Design Therapeutics.
Collegium Pharmaceutical has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Collegium Pharmaceutical had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 2 mentions for Design Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.23 beat Design Therapeutics' score of 0.62 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.
Collegium Pharmaceutical has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.
56.6% of Design Therapeutics shares are owned by institutional investors. 2.5% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Collegium Pharmaceutical has a net margin of 5.13% compared to Design Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 97.28% beat Design Therapeutics' return on equity.
Summary
Collegium Pharmaceutical beats Design Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DSGN) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access